Here's Why Astrazeneca (AZN) is a Strong Value Stock

AstraZeneca (AZN) is highlighted as a strong value stock by Zacks, receiving a Zacks Rank #3 (Hold) with a VGM Score of A and a Value Style Score of B, supported by a forward P/E of 16.58. This assessment follows recent upward revisions to fiscal 2025 earnings estimates by six analysts, raising the consensus to $4.58 per share, and the company's consistent +3.5% average earnings surprise. The analysis, leveraging Zacks' proprietary ranking and Style Scores methodology, positions AZN as a compelling consideration for investors seeking value.

Analysis

AstraZeneca (AZN) presents a compelling, albeit mixed, profile according to the provided Zacks analysis. The company carries a neutral Zacks Rank #3 (Hold), which is counterbalanced by a top-tier 'A' grade for its composite VGM (Value, Growth, Momentum) Score and a strong 'B' for its Value Style Score. This value proposition is quantitatively supported by an attractive forward P/E ratio of 16.58. The positive outlook is further reinforced by fundamental momentum in analyst sentiment, with six analysts revising fiscal 2025 earnings estimates upward over the last 60 days. This has lifted the consensus earnings per share forecast by $0.08 to $4.58. Historically, the company has demonstrated an ability to exceed expectations, reflected in an average earnings surprise of +3.5%. While the headline is strongly positive, the underlying 'Hold' recommendation suggests that despite strong value and positive earnings revisions, the stock may lack immediate-term catalysts for significant outperformance relative to higher-ranked peers within the Zacks framework.

Key Decisions for Investors

• Value-oriented investors should consider AZN's B-rated value score and forward P/E of 16.58 as a positive signal, warranting its position on a watchlist or as a core holding despite the neutral #3 (Hold) rank.
• The primary indicator to monitor is a potential upgrade in the Zacks Rank; a shift to a #2 (Buy) or #1 (Strong Buy) would create a powerful confirmation signal when combined with the existing A-rated VGM score.
• Given the rising consensus estimate for fiscal 2025, investors should pay close attention to upcoming earnings reports to validate that corporate performance and forward guidance align with the recent positive analyst revisions.